Quick Answer
Editas Medicine, Inc. reported Research And Development Expense of $89.95 million for the year ending 2025.
- Editas Medicine, Inc. showed a decrease of -54.9% in Research And Development Expense from 2024 to 2025.
- This data is from Editas Medicine, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2015: $1.89 million | Q2 2015: $7.28 million | Q3 2015: $3.85 million | Q1 2016: $8.88 million | Q2 2016: $10.43 million | Q3 2016: $10.83 million | Q1 2017: $19.02 million | Q2 2017: $17.32 million | Q3 2017: $20.40 million | Q1 2018: $21.30 million | Q2 2018: $32.72 million | Q3 2018: $17.44 million | Q1 2019: $15.84 million | Q2 2019: $23.57 million | Q3 2019: $22.70 million | Q1 2020: $34.57 million | Q2 2020: $28.01 million | Q3 2020: $33.92 million | Q1 2021: $41.94 million | Q2 2021: $33.75 million | Q3 2021: $29.27 million | Q1 2022: $37.98 million | Q2 2022: $43.66 million | Q3 2022: $41.33 million | Q1 2023: $37.80 million | Q2 2023: $29.78 million | Q3 2023: $40.51 million | Q1 2024: $48.79 million | Q2 2024: $54.21 million | Q3 2024: $47.64 million | Q1 2025: $26.59 million | Q2 2025: $16.18 million | Q3 2025: $19.78 million.
- Over the full 12 years of available data (2014 to 2025), Editas Medicine, Inc.'s Research And Development Expense has grown by 1,673.2%.
- Historical annual values: Fiscal year 2025: $89.95 million | Fiscal year 2024: $199.25 million | Fiscal year 2023: $177.65 million | Fiscal year 2022: $174.96 million | Fiscal year 2021: $142.51 million | Fiscal year 2020: $158.00 million | Fiscal year 2019: $96.90 million | Fiscal year 2018: $90.65 million | Fiscal year 2017: $83.16 million | Fiscal year 2016: $56.98 million | Fiscal year 2015: $18.85 million | Fiscal year 2014: $5.07 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: